Anti-Diabetes Drugs - Philippines

Philippines

The Anti-Diabetes Drugs market in the Philippines is set to achieve a revenue of US$172.90m by 2024.
Looking ahead, the market is anticipated to experience a steady compound annual growth rate (CAGR 2024-2028) of 6.30%, reaching a market volume of US$220.80m by 2028.
When compared globally, it is noteworthy that United States will generate the highest revenue, amounting to US$35,630.00m in 2024.
Philippines is witnessing a growing demand for anti-diabetes drugs due to the increasing prevalence of diabetes in the country.

Key regions: India, Canada, Australia, France, Italy

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Diabetes Drugs market in Philippines is a growing industry that has seen a significant increase in demand over the past few years.

Customer preferences: The increasing prevalence of diabetes in the Philippines has led to a higher demand for anti-diabetes drugs. Patients are looking for drugs that are effective, affordable, and have minimal side effects. Additionally, patients are increasingly turning to natural and alternative treatments, such as herbal remedies, to manage their diabetes.

Trends in the market: One of the major trends in the Anti-Diabetes Drugs market in Philippines is the increasing adoption of combination therapies. Combination therapies involve the use of two or more drugs to manage diabetes, and are becoming more popular due to their effectiveness in managing blood sugar levels. Another trend is the increasing availability of generic drugs, which are more affordable than branded drugs and are becoming more widely used in the Philippines.

Local special circumstances: The Philippines has a large population of low-income individuals who may not have access to expensive branded drugs. As a result, there is a high demand for affordable generic drugs in the country. Additionally, the Philippine government has implemented a number of programs to improve access to healthcare, including the Universal Health Care Law, which aims to provide all Filipinos with access to quality healthcare services.

Underlying macroeconomic factors: The Anti-Diabetes Drugs market in Philippines is being driven by a number of macroeconomic factors, including the increasing prevalence of diabetes in the country, the growing middle class, and the government's focus on improving access to healthcare. Additionally, the Philippines has a large and growing pharmaceutical industry, which is contributing to the growth of the Anti-Diabetes Drugs market in the country.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.